+91 789 2456 581 | info@nckpharma.com

Pharma News

Keep updating your pharma knowledge
5 May 2020

Ipsen agreement with IRICoR & Université de Montréal to acquire exclusive license for discovery-stage oncology programme

Ipsen, a global specialty-driven biopharmaceutical group, IRICoR, a pan-Canadian research commercialization center focused on drug discovery, and Université de Montréal, announced they entered into an option agreement by which Ipsen would acquire an exclusive license for the worldwide rights to a high-value oncology programme.

Under the leadership of Université de Montréal’s drug discovery unit based at the Institute for Research in Immunology and Cancer, the programme, currently at lead optimization stage, will focus on advancing the current lead molecules to the development candidate stage. Université de Montréal/IRICoR will be responsible for conducting and financing the research program until the option to license is exercised. If Ipsen decides to exercise the option, Ipsen would assume all development activities and commercialize the drug candidate globally. The financial terms of the agreement, including research, development, commercial milestones and royalties have not been disclosed.

Leave a Reply

Scale up your Pharma knwledge to Next Level with our Free Content

Case studies & Caselets
Simulation based learning
Online self competency assessment tests 

etc.